Haematology

Doç. Dr. Lale Aydın Kaynar

Doctor and researcher Ankara Etlik Şehir Hastanesi Ankara
SepsisMycosesLeukemia, Myeloid, Acute
Open institution page
Suggest a correction

Is this your profile? Claim it and verify your details.

Claim profile

Person ↔ Disease

Which diseases does this doctor work on?

From source
  • Sepsis 2 publications
    Source: OpenAlex / PubMed MeSHView publications
  • Mycoses 2 publications
  • Leukemia, Myeloid, Acute 2 publications

Trust

Where does this information come from?

The source is stated next to each piece of information. If you see something wrong, you can suggest a correction.

  • SpecialtyHaematologysaglik.gov.trFrom source
  • InstitutionAnkara Etlik Şehir Hastanesisaglik.gov.trFrom source
  • Area of workSepsisExtracted from 2 publications · Model version —From source
  • Publications30 publicationsOpenAlex, Europe PMCFrom source
  • ORCID0000-0003-1539-077XORCIDFrom source
  • Last synchronised7 November 2026 00:02https://etliksehir.saglik.gov.tr/TR-864307/klinik-doktorlarimiz.html#lale-aydin-kaynarsaglik.gov.tr

Scientific work

Publications on Sepsis

30 publications

  1. Comparative prognostic performance of ELN 2022 and ELN 2024 risk classifications in a Turkish cohort of acute myeloid leukemia patients receiving hypomethylating agents and BCL-2 inhibitors

    Acta Medica, 2026

    DOI 10.32552/actamedica.2026.1271 Open-access full textSource: OpenAlex

  2. C-Reactive Protein-to-Albumin Ratio (CAR) as a Prognostic Biomarker in Newly Diagnosed Acute Myeloid Leukemia Treated with Intensive Induction Therapy: A Single-Center Retrospective Cohort Study

    Hitit Medical Journal, 2026

    DOI 10.52827/hititmedj.2012111 Open-access full textSource: OpenAlex

  3. Thrombotic and hemorrhagic complications in NPM1-mutated AML: Association with APL-like immunophenotype and impact on early mortality

    Journal of Thrombosis and Thrombolysis, 2026

    DOI 10.1007/s11239-026-03410-4 PMID 42878784 Source: OpenAlex

  4. Prognostic Impact of Serum Albumin Levels at Diagnosis in Patients with Chronic Lymphocytic Leukemia

    Journal of clinical medicine, 2026

    DOI 10.3390/jcm15031315 PMID 41682996 Open-access full textSource: Europe PMC

  5. Adherence to prophylaxis in adults with hemophilia: the role of communication, self-ınfusion, and ınfusion timing

    Journal of Current Hematology & Oncology Research, 2026

    DOI 10.51271/jchor-0080 Open-access full textSource: OpenAlex

  6. Overview of Acute Myeloid Leukemia with TP53 Mutation: Single Center, Real-Life Data

    Hitit Medical Journal, 2025

    DOI 10.52827/hititmedj.1628279 Open-access full textSource: OpenAlex

  7. Prognostic value of hyperlactatemia and lactate clearance in septic patients with hematological malignancies

    Annals of Hematology, 2024

    DOI 10.1007/s00277-024-05977-5 PMID 39235491 6 citations (OpenAlex) Open-access full textSource: OpenAlex

  8. Long-term Results of Imatinib Discontinuation in Patients with Chronic-phase Chronic Myeloid Leukemia: A National Multicenter Prospective Study

    Turkish journal of haematology : official journal of Turkish Society of Haematology, 2023

    DOI 10.4274/tjh.galenos.2023.2023.0194 PMID 37877113 2 citations (Europe PMC) Open-access full textSource: Europe PMC

  9. Salvage Autologous Hematopoietic Stem Cell Transplantation Versus Chemoimmunotherapy in Relapsed Multiple Myeloma Patients After First Transplantation; Single Center Data

    Journal of Ankara University Faculty of Medicine, 2023

    DOI 10.4274/atfm.galenos.2023.83713 Open-access full textSource: OpenAlex

  10. Is flow cytometry useful in determining central nervous system involvement in patients with hematological malignancy? Analysis with a prospective cohort

    Leukemia Research, 2023

    DOI 10.1016/j.leukres.2023.107332 PMID 37307678 7 citations (OpenAlex) Source: OpenAlex

View all 30 publications